Spravato, developed by Janssen Pharmaceuticals, is an innovative nasal spray containing esketamine, a chemical mirror image of ketamine. Initially used as an anesthetic and dissociative agent, ketamine has been studied for its potential antidepressant and anxiolytic effects. Spravato, with its rapid action and unique mechanism of action, has been approved by the FDA for treatment-resistant depression and is now showing promise in addressing social anxiety.